Brad E Hoffman

Brad E Hoffman, PhD

Associate Professor

Department: MD-PEDS-CELL / MOLEC THERP DIV
Business Phone: (352) 273-8152
Business Email: bhoffman@ufl.edu

About Brad E Hoffman

Associate Professor,

Department of Pediatrics

Department of Neuroscience

Lab Website http://hoffman.pediatrics.med.ufl.edu/

Honors & Awards

Research Scientist Award
2018 · National multiple sclerosis society
Ambassador
2017-current · NIH-LRP Program
Recipient, Travel Grant
2016 · American Association of Immunologists
Recipient, Travel Grant
2016 · International Congress of Immunology
Mentor S.T.E.M Supernova
2015-current · Boy Scouts of America
Immunology Grant Recipient
2011 · BD Bioscience
Award in Hemophilia Research (ASPIRE)
2011 · Pfizer Pharmaceuticals
Kokomoor Award for Excellence in Pediatric Research
2010 · University of Florida, Department of Pediatrics
Research Fellowship
2007 · American Heart Association

Research Profile

The major focus of my research program is aimed at understanding and exploiting the unique molecular and cellular mechanisms required for the induction of immunological tolerance. As such, my research group is developing novel immunotherapies using the Adeno-associated virus (AAV) gene-therapy platform that are capable of inducing tolerogenic antigen-specific regulatory T cells (Tregs) as a therapeutic intervention for autoimmune and genetic disease such as Multiple Sclerosis. Recently, we were the first to demonstrate that an AAV vector could be used therapeutically to not only prevent development of disease, but to also abrogate preexisting (reverse) disease in multiple mouse models of Multiple Sclerosis.

Areas of Interest
  • Adeno-Associated Viral Gene Therapy
  • Autoimmune Disease
  • Gene therapy
  • Immune Tolerance
  • Immunotherapy
  • Multiple Sclerosis

Publications

2017 American Journal of Respiratory Cell and Molecular Biology
2010 Proceedings of the National Academy of Sciences of the United States of America

Grants

Oct 2019 ACTIVE
Sarepta TO #8 – Vector production for in vivo studies to determine candidate
SAREPTA THERAPEUTICS · Principal Investigator
Oct 2019 ACTIVE
Disease modifying therapy testing in combination with gene therapy
SAREPTA THERAPEUTICS · Principal Investigator
Oct 2019 ACTIVE
Treg depletion studies to prove mechanism is immune tolerance
SAREPTA THERAPEUTICS · Principal Investigator
Oct 2019 ACTIVE
Task Order 6 – Mouse models for continued discovery and determining optimal vector
SAREPTA THERAPEUTICS · Principal Investigator
Sep 2019 ACTIVE
Engineering AAV for safe and efficient gene delivery to the human retina
NATL INST OF HLTH NEI ·
Dec 2018 – Nov 2019
Identifying optimal CD8 Treg for CAR Treg Therapy
AMERICAN SOCIETY OF GENE AND CELL THERAP · Mentor
Sep 2017 ACTIVE
Immune modulation and CNS pathology following exogenous a-synuclein challenge
NATL INST OF HLTH NINDS ·
Jan 2017 ACTIVE
Restoring Immune Tolerance in a Model of Multiple Sclerosis
NATL INST OF HLTH NIAID · Principal Investigator
Apr 2015 – Mar 2019
In Vivo Induction of Antigen Specific T-Cell Tolerance to a Neuro-Antigen by AAV Hepatic Gene Therapy
NATL MULTIPLE SCLEROSIS SOC · Principal Investigator

Patents

Published April 2015
AAV-Based Gene Therapy for Multiple Sclerosis
#US2017/0043036

Education

PhD Immunology
2006 · Temple University School of Medicine
BS Chemistry & Biology
1994 · University of Central Florida

Contact Details

Phones:
Business:
(352) 273-8152
Emails:
Business:
bhoffman@ufl.edu
Addresses:
Mailing:
2033 MOWRY RD
PO BOX 103610
CGRC 207
GAINESVILLE FL 326103010
Physical:
2203 MOWRY RD
GAINESVILLE FL 32611